Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects

NCT00707746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Diseases
Hyperlipidemias
Metabolic Disorder
Hypercholesterolemia
Dyslipidemias
Lipid Metabolism Disorders

Interventions

DRUG: mipomersen
DRUG: placebo

Sponsor

Kastle Therapeutics, LLC

Collaborators

[object Object]